Phaseline

Targets › CEBPA

CEBPA (CCAAT/enhancer-binding protein alpha): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Apr 2027.

Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. (UniProt, P49715)

Open in Phaseline: the race on CEBPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National University Hospital, SingaporeMTL-CEBPA
RNA oligonucleotide targeting CEBPA (C/EBP-alpha)
CEBPAPhase 1Advanced Hepatocellular CarcinomaApr 2027
Pacylex Pharmaceuticalszelenirstat (PCLX-001)
C/EBP alpha activator
CEBPAPhase 1Relapsed Adult AML–

Conditions

Advanced Hepatocellular Carcinoma (1) Relapsed Adult AML (1)

Modalities

mixed (1), small molecule (1)

Companies

National University Hospital, Singapore (1) Pacylex Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.